Table 1.
Characteristics of 1,222 raltegravir eligible patients, by residence
| Characteristic | Urban N = 989 (80.9%) |
Rural N = 233 (19.1%) |
χ2 (df)* | P |
|---|---|---|---|---|
| Age | ||||
| 0–40 | 100 (10.1) | 19 (8.1) | 0.84 (3) | 0.84 |
| 41–50 | 349 (35.3) | 84 (36.1) | ||
| 51–60 | 412 (41.7) | 100 (42.9) | ||
| 61 plus | 128 (12.9) | 30 (12.9) | ||
| Gender | ||||
| Male | 963 (97.4) | 227 (97.4) | 0.002 (1) | 0.96 |
| Female | 26 (2.6) | 6 (2.6) | ||
| Race/ethnicity | ||||
| Black | 576 (58.2) | 96 (41.2) | 24.3 (1) | < 0.001 |
| White, non-hispanic | 324 (32.8) | 113 (48.5) | ||
| Other | 71 (7.2) | 17 (7.3) | ||
| Missing | 18 (1.8) | 7 (3.0) | ||
| CD4 count | ||||
| 0–50 | 398 (40.2) | 109 (46.8) | 24.5 (5) | <0.001 |
| 51–200 | 173 (17.5) | 35 (15.0) | ||
| 201–350 | 176 (17.8) | 29 (12.4) | ||
| 351–500 | 98 (9.9) | 18 (7.7) | ||
| >500 | 132 (13.4) | 29 (12.5) | ||
| Missing | 12 (1.2) | 13 (5.6) | ||
| AIDS defining illness | ||||
| Yes | 197 (19.9) | 43 (18.5) | 0.26 (1) | 0.61 |
| No | 792 (80.1) | 190 (81.5) | ||
| Substance abuse | ||||
| Yes | 249 (25.2) | 45 (19.3) | 3.55 (1) | 0.06 |
| No | 749 (74.8) | 188 (80.7) | ||
| HIV viral load | ||||
| 401–999 | 224 (22.6) | 66 (28.4) | 5.6 (3) | 0.13 |
| 1,000–9,999 | 323 (32.7) | 80 (34.3) | ||
| 10,000–99,999 | 303 (30.6) | 56 (24.0) | ||
| 100,000 plus | 139 (14.1) | 31 (13.3) | ||
| Years on ART | ||||
| Median (IQR) | 11 (8–12) | 11 (7–12) | −0.05† | 0.96 |
| ART adherence | ||||
| Median (IQR) | 0.73 (0.52–0.90) | 0.74 (0.54–0.92) | −1.39† | 0.17 |
*
Chi-square value (degrees of freedom)
†
Wilcoxon rank sum Z statistic is given for continuous measures, years on ART and ART adherence